Fig 1.
Chemical structure of ponatinib (PNT) and Vandetanib (IS).
Fig 2.
TIC chromatogram of MRM of PNT (5–400 ngmL-1) and IS (100 ngmL-1).
Fig 3.
MRM mass spectra and the expected fragmentation pathway of (a) PNT and (b) vandetanib (IS).
Table 1.
Data of back-calculated PNT concentration of the calibration standards from RLMs and plasma matrices.
Table 2.
Intra-day and inter-day precision and accuracy of the proposed methods.
Table 3.
Recovery of QC samples for determining the concentration of PNT in plasma and RLMs matrix.
Table 4.
PNT Stability data and dilution integrity in plasma matrix under different conditions.
Table 5.
PNT Stability data and dilution integrity in RLMs matrix under different conditions.
Fig 4.
The metabolic stability profile of PNT after incubation with RLMs.
Metabolic reaction was stopped at different time points.